Clinical and prognostic value of hTERT mRNA expression in patients with non-small-cell lung cancer

• Authors: Marzena Zalewska-Ziob , Katarzyna Dobija-Kubica , Krzysztof Biernacki , Brygida Adamek , Janusz Kasperczyk , Krzysztof Bruliński , Zofia Ostrowska
• Languages of publication: EN

Abstracts

EN

Telomerase, undetectable in normal somatic cells, plays a critical role in carcinogenesis of the majority of human tumors including lung carcinoma. The aim of our study was to determine human telomerase reverse transcriptase (hTERT) mRNA expression in patients with non-small cell lung cancer (NSCLC) in order to estimate its usefulness as diagnostic and/or prognostic factor. hTERT expression was analyzed in a group of 12 females and 28 males with NSCLC using Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR method) in cancerous and non-cancerous lung tissues. Results were analyzed according to clinical data and one-, two-, and five-year survival rates. hTERT expression in the cancerous tissue was significantly higher than in the lung parenchyma free from neoplasm infiltration (p<0.05). There was no significant association between hTERT expression in the tumor tissue and age, gender, grading or clinical stage. A significant difference in hTERT expression between two types of histopathological patterns (adenocarcinoma and squamous cell carcinoma) was detected (p=0.01). No association between hTERT expression in NSCLC specimens and survival rates was found. hTERT mRNA detection by QRT-PCR in tumor and corresponding cancer-free tissues can be used as a diagnostic marker in patients with NSCLC, but seems not to be a prognostic factor.

Keywords

EN

non-small-cell lung cancer; telomerase; hTERT expression; survival rate; prognosis

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2017
• Volume: 64
• Issue: 4
• Pages: 641-646

Dates

published

2017

received

2017-06-03

revised

2017-07-27

accepted

2017-09-10

(unknown)

2017-11-15

Contributors

author

Marzena Zalewska-Ziob

• Chair and Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

author

Katarzyna Dobija-Kubica

• John Paul II Hospital of Oncology, General Surgery Ward, Bielsko Biała, Poland

author

Krzysztof Biernacki

• Chair and Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

author

Brygida Adamek

• Department of Basic Medical Sciences, School of Public Health in Bytom, Medical University of Silesia, Katowice, Poland

author

Janusz Kasperczyk

• Chair and Department of Environmental Medicine and Epidemiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

author

Krzysztof Bruliński

• Specialist Hospital of Lung Diseases and Tuberculosis, Thoracic Surgery Ward, Bystra Śląska, Poland

author

Zofia Ostrowska

• Chair and Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

References

• Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, Klimstra D, Venkatraman E, Moore MA, Dmitrovsky E (1997) High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 89: 1609-1615.
• Armanios M, Blackburn EH (2012) The telomere syndromes. Nat Rev Genet 13: 693-704. doi: 10.1038/nrg3246.
• Chen CH, Chen RJ (2011) Prevalence of telomerase activity in human cancer. J Formos Med Assoc 110: 275-289.
• Dobija-Kubica K, Zalewska-Ziob M, Bruliński K, Rogoziński P, Wiczkowski A, Gawrychowska A, Gawrychowski J (2016) Telomerase activity in non-small cell lung cancer. Kardiochir Torakochirurgia Pol 13: 15-20.
• Driscoll B, Buckley S, Bui KC, Anderson KD, Warburton D (2000) Telomerase in alveolar epithelial development and repair. Am J Physiol Lung Cell Mol Physiol 279: L1191-L1198.
• Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC (2010) Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw 8: 740-801.
• Fujita Y, Fujikane T, Fujiuchi S, Nishigaki Y, Yamazaki Y, Nagase A, Shimizu T, Ohsaki Y, Kikuchi K (2003) The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with non-small cell lung carcinoma. Cancer 98: 1008-1013.
• Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V (2007) The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2: 706-714.
• Hara H, Yamashita K, Shinada J, Yoshimura H, Kameya T (2001) Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer. Lung Cancer 34: 219-226.
• Hashim M, Sayed M, Samy N, Elshazly S (2011) Prognostic significance of telomerase activity and some tumor markers in non-small cell lung cancer. Med Oncol 28: 322-330.
• Hiyama E, Hiyama K, Yokoyama T, Shay (2001) Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 3: 17-26.
• Hiyama E, Hiyama K (2001) Clinical utility of telomerase in cancer. Oncogene 21: 643-649.
• Jafri MA, Ansari SA, Alqahtani MH, Shay JW (2016) Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med 8: 69. doi: 10.1186/s13073-016-0324-x.
• Kim NW (1997) Clinical implications of telomerase in cancer. Eur J Cancer 33: 781-786.
• Kumaki F, Kawai T, Hiroi S, Shinomiya N, Ozeki Y, Ferrans VJ, Torikata C (2001) Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 32: 188-195.
• Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using Real-Time Quantitative PCR and the 2-ΔΔCT method. Methods 25: 402–408.
• Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FR (2004) Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22: 4575-4583.
• Marchetti A, Bertacca G, Buttitta F, Chella A, Quattrocolo G, Angeletti CA, Bevilacqua G (1999) Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res 5: 2077-2081.
• Marchetti A, Pellegrini C, Buttitta F, Falleni M, Romagnoli S, Felicioni L, Barassi F, Salvatore S, Chella A, Angeletti CA, Roncalli M, Coggi G, Bosari S (2002) Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Invest 82: 729-736.
• Metzger R, Vallbohmer D, Muller-Tidow C, Higashi H, Bollschweiler E, Warnecke-Eberz U, Brabender J, Baldus SE, Xi H, Berdel WE, Serve H, Hoelscher AH, Schneider PM (2009) Increased human telomerase reverse transcryptase mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer. Anticancer Res 29: 1157-1162.
• Mocellin S, Pooley KA, Nitti D (2013) Telomerase and the search for the end of cancer. Trends Mol Med 19: 125-33. doi: 10.1016/j.molmed.2012.11.006.
• Palm W, de Lange T (2008) How shelterin protects mammalian telomeres. Annu Rev Genet 42: 301-334. doi: 10.1146/annurev.genet.41.110306.130350.
• Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
• Radziszewska A, Karczmarek-Borowska B, Gradalska-Lampart M, Filip AA (2015) Epidemiology, prevention and risk morbidity factors for lung cancer. Pol Merkur Lekarski 38: 113-118.
• Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791.
• Shay JW, Wright WE (2000) Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol 1: 72-76. doi: 10.1038/35036093.
• Shay JW, Wright WE (2005) Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 26: 867-874.
• Specht K, Richter T, Müller U, Walch A, Werner M, Höfle H (2001) Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158: 419-429. doi: 10.1016/S0002-9440(10)63985-5.
• Van den Berg RM, Brokx H, Vesin A, Field JK, Brambilla C, Meijer CJ, Sutedja GT, Heideman DA, Postmus PE, Smit EF, Snijders PJ (2010) Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project. Int J Oncol 37: 455-461.
• Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR (2002) hTERT expression is a prognostic factor of survival in patients with stage I non-smal cell lung cancer. Clin Cancer Res 8: 2883-2889.
• Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB (1997) Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 17: 498-502.

Identifiers

DOI

10.18388/abp.2017_1618